Neurophet and ALZ-NET sign MoU on Alzheimer’s therapies
By Salong Debbarma
Published on March 27, 2026.
South Korean AI company Neurophet has signed a memorandum of understanding (MoU) with the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) to facilitate imaging monitoring infrastructure for therapies related to the disease. The agreement aims to support healthcare professionals participating in ALZ-net while improving the quality of care for Alzheimer's patients. Key products in this partnership include Neurophetamine Aqua, a brain neurodegeneration imaging analysis tool, Neurophenche Scale PET, and the Neurophendic Plus integrated brain imaging product. All three solutions hold 510(k) clearance from the US Food and Drug Administration (FDA).
Related Articles
After two jury verdicts against social media companies, it’s time to re-examine your kids’ tech use
Parents should re-examine their children’s social media use following jury verdicts that deem it addictive, harmful, and requires intervention.
The Peptide Secret Big Pharma Has Been Sitting On – And Why You Finally Don’t Need a Needle to Get It
The Wellness Company’s AQA™ delivery technology enhances gut resilience, improves performance, and removes unnecessary needle-based restrictions to prevent chronic inflammation.
Synesthesia isn't just in your mind. The body reacts as if the colors were real.
A study reveals that people with synesthesia experience different pupil reactions compared to real-world color experiences, enhancing understanding of visual illusions.